{"id":"anti-il-2r","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of infections"}]},"_chembl":{"chemblId":"CHEMBL6042642","moleculeType":null,"molecularWeight":"381.27"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the interleukin-2 receptor, anti-IL-2R drugs inhibit the activation of T-cells, which play a key role in the immune response. This mechanism is particularly useful in treating autoimmune diseases and preventing transplant rejection.","oneSentence":"anti-IL-2R drugs target the interleukin-2 receptor to prevent T-cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:01:46.729Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in kidney transplant recipients"}]},"trialDetails":[{"nctId":"NCT04409080","phase":"PHASE1","title":"REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-01-13","conditions":"Severe Aplastic Anemia (SAA)","enrollment":17},{"nctId":"NCT01011205","phase":"PHASE3","title":"Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09-30","conditions":"Liver Transplantation","enrollment":893},{"nctId":"NCT04936841","phase":"PHASE2","title":"Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2021-08-05","conditions":"Head and Neck Cancer","enrollment":5},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT00001962","phase":"PHASE2","title":"A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure","status":"TERMINATED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-11","conditions":"Aplastic Anemia, Pure Red Cell Aplasia, Diamond Blackfan Anemia","enrollment":100},{"nctId":"NCT00632827","phase":"PHASE2","title":"Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-07-01","conditions":"Peripheral T-Cell Lymphoma","enrollment":21},{"nctId":"NCT00001526","phase":"PHASE1","title":"ANTI-TAC THERAPY FOR UVEITIS","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"1996-06-04","conditions":"Uveitis","enrollment":15},{"nctId":"NCT00025662","phase":"PHASE2","title":"Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2001-05","conditions":"Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia","enrollment":23},{"nctId":"NCT00859131","phase":"NA","title":"Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2009-03","conditions":"End Stage Renal Disease","enrollment":200},{"nctId":"NCT02005562","phase":"PHASE3","title":"OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Kidney Transplantation","enrollment":252},{"nctId":"NCT00604357","phase":"PHASE3","title":"CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2008-12","conditions":"End Stage Liver Disease, Impaired Renal Function","enrollment":27},{"nctId":"NCT00321074","phase":"PHASE3","title":"Tacrolimus and Daclizumab Versus Tacrolimus and Steroids in Liver Recipients Receiving Sub-optimal Grafts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2005-05","conditions":"LIVER TRANSPLANTATION","enrollment":101},{"nctId":"NCT00295594","phase":"PHASE3","title":"Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2005-03","conditions":"Liver Transplantation","enrollment":627},{"nctId":"NCT00693524","phase":"PHASE2","title":"Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-11","conditions":"Liver Transplantation","enrollment":94},{"nctId":"NCT00295607","phase":"PHASE2","title":"Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2005-06","conditions":"Hepatitis C, Liver Transplantation","enrollment":138},{"nctId":"NCT00001941","phase":"PHASE1, PHASE2","title":"Anti-Tac for Treatment of Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-12","conditions":"HTLV-I Infection, T Cell Leukemia","enrollment":34},{"nctId":"NCT00658073","phase":"NA","title":"Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts","status":"COMPLETED","sponsor":"Fuzhou General Hospital","startDate":"2008-03","conditions":"Renal Transplant Rejection","enrollment":165},{"nctId":"NCT00073047","phase":"PHASE2","title":"Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Facet Biotech","startDate":"2003-04","conditions":"Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease","enrollment":150},{"nctId":"NCT00682292","phase":"PHASE3","title":"Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2001-05","conditions":"Renal Transplantation","enrollment":227},{"nctId":"NCT00049725","phase":"PHASE2","title":"Daclizumab to Treat Chronic Immune Thrombocytopenia","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2002-11","conditions":"Thrombocytopenia","enrollment":24},{"nctId":"NCT00001249","phase":"PHASE1","title":"Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1989-12","conditions":"Leukemia, T-Cell, Lymphoma, T-Cell, Cutaneous","enrollment":30},{"nctId":"NCT00072969","phase":"PHASE2","title":"A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2003-11","conditions":"Myelodysplastic Syndromes","enrollment":132},{"nctId":"NCT00043667","phase":"PHASE2","title":"Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2002-08","conditions":"Uveitis","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":267,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"anti-IL-2R","genericName":"anti-IL-2R","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"anti-IL-2R drugs target the interleukin-2 receptor to prevent T-cell activation. Used for Prevention of organ rejection in kidney transplant recipients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}